Search results
Showing 8896 to 8905 of 8905 results
14,000 women at risk of fractures after the menopause to benefit from bone disease drug
Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.
25 years of NICE and focusing on what matters most to deliver for the future
Home News Podcasts 25 years of NICE and focusing on what matters most to deliver for the future Podcasts 01 May 2024 Listen About this episode
Home News Podcasts Assessing the familial and genetic risk of ovarian cancer Podcasts 03 April 2024 Listen About this episode We talk to Ranjit
Learn more about the NICE and NHS England MedTech Pathway consultation
Home News Podcasts Learn more about the NICE and NHS England MedTech Pathway consultation Podcasts 03 June 2024 Listen About this episode
Learn more about NICE's new guideline on identifying and managing adrenal insufficiency
Home News Podcasts Learn more about NICE's new guideline on identifying and managing adrenal insufficiency Podcasts 29 August 2024 Listen
Find out about the role of NICE's independent advisory committees
Home News Podcasts Find out about the role of NICE's independent advisory committees Podcasts 31 October 2024 Listen About this episode We
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
NICE recommends pembrolizumab for colorectal cancer patients with rare mutations.
Shared decision making recommendations will ensure people are at the heart of healthcare
NICE’s new guideline on shared decision making will help transform people’s experiences of health and social care.
NICE joins the shared commitment to public involvement in research
Working alongside people and communities is an essential tool in helping to improve?the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.